AB-106 is an efficient and selective ROS1/NTRK dual-target inhibitor with which phase I clinical trials in Japan and the United States have been completed with promising results. We expect to start global phase II clinical trials in the first quarter of 2020;
AB-106 is believed to have the following characteristics:
- It is a very selective and efficient inhibitor of ROS1 and NTRK1-3 and is also effective against ROS1 G2032R- a major Crizotinib resistance mutation.
- High response rate, long effective duration, and long progression free survival (PFS) period;
- It is also effective in patients with ROS1-positive non-small cell lung cancer and brain metastases who have failed crizotinib treatment with acceptable level of safety;
- tumor-agnostic in that it is effective to many tumors types as long as, ROS1 or NTRK fusion mutations are present similar to larotrectinib and entrectinib